No title
2593Background: PD-1 blockade has demonstrated positive anti-tumor activity across multiple tumor types. While the anti-tumoral response can be substantial and even curative, response rates remain low in many cancer types. Long-lasting responses are only observed in a minority of patients, and additional immunotherapeutic alternatives remain limited for patients who fail to respond or initially re
